{"id":21049,"date":"2022-10-17T22:32:11","date_gmt":"2022-10-17T20:32:11","guid":{"rendered":"https:\/\/www.izb-online.de\/adivo-erhaelt-25-mio-euro-eu-foerderung\/"},"modified":"2022-10-17T22:39:51","modified_gmt":"2022-10-17T20:39:51","slug":"adivo-erhaelt-25-mio-euro-eu-foerderung","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/adivo-receives-euro-25-million-eu-grant\/","title":{"rendered":"adivo receives \u20acuro 2.5 million EU grant"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

adivo receives \u20acuro 2.5 million EU grant<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]The grant will be used to accelerate the development of new therapies for inflammatory bowel diseases in companion animals[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]October 2022[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”15970″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Adivo GmbH[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Katrin Ladetzki-Baehs, CEO and Dr. Markus Waldhuber, Co-Founder and Chief Development Officer of adivo GmbH (f.l.t.r.)[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text]<\/p>\n

\u201cThe grant funding by the EIC Accelerator program adds to our growing financial muscle and will support adivo in competing for an industry-leading position in the companion antibody therapeutics market.\u201d<\/h6>\n

Dr. Markus Waldhuber
\nCo-Founder and Chief Development Officer of adivo GmbH<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]adivo GmbH, a leader in discovering species-specific therapeutic antibodies for pets, announced on October 17, 2022 that the company will benefit from an approved European Innovation Council (EIC) Accelerator grant to support one of its pipeline programs. The grant has a total volume of EUR 2.5 million and will help accelerate the development of adivo\u2019s proprietary therapeutic antibody program, addressing the growing need for novel therapeutic options for dogs suffering from inflammatory bowel disease (IBD).<\/p>\n

\u201cIBD is affecting a growing number of dogs and their owners worldwide. By transferring a therapeutic principle and target biology that is well validated in humans in a species-specific manner, we aim to provide a best-in-class therapeutic solution for IBD in dogs,\u201c commented Dr. Markus Waldhuber, Co-Founder and Chief Development Officer of adivo. \u201cadivo is entering a transformative chapter in its development as two programs are approaching the initiation of first-in-animal studies. The grant funding by the EIC Accelerator program adds to our growing financial muscle and will support adivo in competing for an industry-leading position in the companion antibody therapeutics market.\u201d<\/p>\n

adivo has established CEASAR, the first fully canine phage display platform in the veterinary medicines market for selecting therapeutic candidates against a broad range of diseases. More recently, the company expanded its technology basis to cover a second companion animal species with significant medical needs and launched FELIX, the first fully synthetic source of therapeutic antibodies on the market to date for cats. The adivo technology platforms allows de-novo identification of species-specific antibodies panels to select drug candidates with optimal functionality, developability and low risk of immunogenicity. Powered by more than two decades of combined therapeutic antibody discovery expertise gained in human medicine, the adivo leadership team is ideally positioned to bring forth developable candidates with best-in-class drug properties and molecular profiles tailored to the targeted species.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n